Hunterian Medicine

Executive Summary

Hunterian Medicine is a San Diego-based gene editing company pioneering a novel platform to overcome the critical challenge of CRISPR delivery. Its patented technology enables efficient, on-target delivery through a single adeno-associated virus (AAV), vastly simplifying the therapeutic use of CRISPR. This innovation opens immediate pathways to develop cures for a wide range of genetic diseases currently lacking FDA-approved therapies. By enabling single-vector delivery of the CRISPR machinery and repair template, Hunterian's platform addresses key limitations in payload capacity and targeting specificity, potentially accelerating the development of treatments for monogenic disorders. The company's 'Approved' stage suggests it has achieved regulatory clarity, positioning it for near-term clinical milestones. With a focus on diseases with high unmet need, Hunterian's platform could significantly impact the gene therapy landscape. Its approach offers a streamlined path to the clinic, and upcoming milestones such as IND filings and partnership announcements are likely to serve as key value inflection points.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for first IND application60% success
• Q4 2026Strategic partnership with major pharmaceutical company for delivery platform50% success
• Q2 2026Publication of key preclinical efficacy data in peer-reviewed journal70% success